Chukwuemeka N Okafor1, Robert L Cook1, Xinguang Chen1, Pamela J Surkan2, James T Becker3, Steve Shoptaw4, Eileen Martin5, Michael W Plankey6. 1. a Department of Epidemiology, College of Public Health and Health Professions, College of Medicine , University of Florida , Gainesville , FL , USA. 2. b Social and Behavioral Interventions Program, Department of International Health , Johns Hopkins Bloomberg School of Public Health , Baltimore , MD , USA. 3. c Departments of Psychiatry, Neurology and Psychology , University of Pittsburgh , Pittsburgh , PA , USA. 4. d David Geffen School of Medicine , Department of Family Medicine at University of California , Los Angeles , USA. 5. e Department of Psychiatry , Rush University Medical Center , Chicago , IL USA. 6. f Georgetown University Medical Center , Department of Medicine, Division of Infectious Diseases , Washington , DC , USA.
Abstract
BACKGROUND: Marijuana use is common among HIV+ individuals, but few studies have examined long-term trends in prevalence and correlates of use. METHODS: We evaluated trends (1984-2013) in the annual prevalence of current (past 6-month use) and daily (among current users) marijuana use and determined correlates of use among 2742 HIV-seropositive (HIV+) and 3172 HIV-seronegative (HIV-) men who have sex with men in the Multicenter AIDS Cohort Study (MACS). Poisson regression models were used to estimate prevalence ratios of marijuana use separately for the men who were enrolled before 2001 (early-cohort) and after 2001 (late-cohort). RESULTS: Over the 29 years of the study, the prevalence of current marijuana use declined significantly, whereas daily use among users increased among all men in the early and late-cohorts. A HIV+ status was associated with higher prevalence of marijuana use among the men in the early-cohort (adjusted prevalence ratio [aPR] = 1.53, 95% confidence interval [CI]:1.42, 1.64, p = <0.0001), but not in the men in the late-cohort (aPR = 0.90, 95% CI: 0.79, 1.03, p = 0.1424). Alcohol use and cigarette smoking were being positively associated with marijuana use. CONCLUSIONS: Although the annual prevalence of current marijuana use decreased significantly over time in the MACS, daily use among users increased significantly. Further, among the HIV+ men, our study did not show clinically significant adverse effects of marijuana use on highly active antiretroviral therapy use, CD4+ count, or HIV viral load.
BACKGROUND:Marijuana use is common among HIV+ individuals, but few studies have examined long-term trends in prevalence and correlates of use. METHODS: We evaluated trends (1984-2013) in the annual prevalence of current (past 6-month use) and daily (among current users) marijuana use and determined correlates of use among 2742 HIV-seropositive (HIV+) and 3172 HIV-seronegative (HIV-) men who have sex with men in the Multicenter AIDS Cohort Study (MACS). Poisson regression models were used to estimate prevalence ratios of marijuana use separately for the men who were enrolled before 2001 (early-cohort) and after 2001 (late-cohort). RESULTS: Over the 29 years of the study, the prevalence of current marijuana use declined significantly, whereas daily use among users increased among all men in the early and late-cohorts. A HIV+ status was associated with higher prevalence of marijuana use among the men in the early-cohort (adjusted prevalence ratio [aPR] = 1.53, 95% confidence interval [CI]:1.42, 1.64, p = <0.0001), but not in the men in the late-cohort (aPR = 0.90, 95% CI: 0.79, 1.03, p = 0.1424). Alcohol use and cigarette smoking were being positively associated with marijuana use. CONCLUSIONS: Although the annual prevalence of current marijuana use decreased significantly over time in the MACS, daily use among users increased significantly. Further, among the HIV+ men, our study did not show clinically significant adverse effects of marijuana use on highly active antiretroviral therapy use, CD4+ count, or HIV viral load.
Entities:
Keywords:
HIV positive and HIV negative; Marijuana; correlates; men who have sex with men; prevalence
Authors: Donald I Abrams; Joan F Hilton; Roslyn J Leiser; Starley B Shade; Tarek A Elbeik; Francesca T Aweeka; Neal L Benowitz; Barry M Bredt; Bradley Kosel; Judith A Aberg; Steven G Deeks; Thomas F Mitchell; Kathleen Mulligan; Peter Bacchetti; Joseph M McCune; Morris Schambelan Journal: Ann Intern Med Date: 2003-08-19 Impact factor: 25.391
Authors: Brian Wells Pence; Nathan M Thielman; Kathryn Whetten; Jan Ostermann; Virender Kumar; Michael J Mugavero Journal: AIDS Patient Care STDS Date: 2008-11 Impact factor: 5.078
Authors: Fabienne Marcellin; Caroline Lions; Eric Rosenthal; Perrine Roux; Philippe Sogni; Linda Wittkop; Camelia Protopopescu; Bruno Spire; Dominique Salmon-Ceron; François Dabis; Maria Patrizia Carrieri Journal: Drug Alcohol Rev Date: 2016-04-13
Authors: Chukwuemeka N Okafor; Michael W Plankey; David Goodman-Meza; Michael Li; Karla J Bautista; Hector Bolivar; Tien C Phyllis; Todd T Brown; Steven J Shoptaw Journal: Drug Alcohol Depend Date: 2020-02-20 Impact factor: 4.492
Authors: Cecilia T Costiniuk; Zahra Saneei; Syim Salahuddin; Joseph Cox; Jean-Pierre Routy; Sergio Rueda; Sara J Abdallah; Dennis Jensen; Bertrand Lebouché; Marie-Josée Brouillette; Marina Klein; Jason Szabo; Charles Frenette; Andreas Giannakis; Mohammad-Ali Jenabian Journal: Cannabis Cannabinoid Res Date: 2019-09-23
Authors: Jessica S Merlin; Dustin Long; William C Becker; Edward R Cachay; Katerina A Christopolous; Kasey R Claborn; Heidi M Crane; Eva Jennifer Edelman; Travis I Lovejoy; William Christopher Mathews; Benjamin J Morasco; Sonia Napravnik; Connall OʼCleirigh; Michael S Saag; Joanna L Starrels; Robert Gross; Jane M Liebschutz Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Chukwuemeka N Okafor; Michael W Plankey; Michael Li; Xinguang Chen; Pamela J Surkan; Steve Shoptaw; Eileen Martin; Ronald Cohen; Ned Sacktor; Robert L Cook Journal: Subst Use Misuse Date: 2019-01-30 Impact factor: 2.164
Authors: Jessica S Merlin; Jeffrey H Samet; Debbie M Cheng; Marlene C Lira; Judith I Tsui; Leah S Forman; Jonathan Colasanti; Alexander Y Walley; Carlos Del Rio; Jane M Liebschutz Journal: J Acquir Immune Defic Syndr Date: 2019-10-01 Impact factor: 3.771